Eye on China-made Heparin ingredients

Share this article:
The FDA examined the wrong factory when assessing the safety of a Chinese-made ingredient used to make Baxter International's blood thinner Heparin. The drug has been recently linked to four deaths and hundreds of reports of allergic reactions.

Investigators are slated to travel to China this week to inspect the factory that produces the drug's main ingredient, said Joseph Famulare, deputy director of the Center for Drug Evaluation and Research's compliance department. The Chinese manufacturer was not initially inspected because it was confused with another company in the agency's database with a similar name, Famulare said in published reports.

As of now, the agency remains unsure as to what exactly is to blame for the deaths and allergic reactions associated with Heaprin.

Inspections are also under way at a Baxter facility in Cherry Hill, NJ, and at company supplier Scientific Protein Laboratories in Waunakee, WI.

Last week the FDA asked healthcare providers to stop using Heparin citing the side effects. In 2007, the FDA received 100 reports of problems with the drug.

Last month, Baxter recalled nine lots of Heparin after learning of allergic reactions among dialysis patients. Problems included dizziness, fainting, and racing heartbeat.
Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...